D-1186-2014 Class III Terminated

Recalled by Lupin Pharmaceuticals Inc. — Baltimore, MD

FDA drug recall D-1186-2014 was initiated by Lupin Pharmaceuticals Inc. on Jan 27, 2014 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications: Product did not meet specification in total impurities at the 9-month stability station. The recall status is terminated (terminated May 12, 2015). Affected quantity: 4,038 bottles.

Recall Details

Product Type
Drugs
Report Date
Apr 9, 2014
Initiation Date
Jan 27, 2014
Termination Date
May 12, 2015
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
4,038 bottles

Product Description

Suprax, Cefixime for Oral Suspension USP 500 mg/5 ml, 10mL (when reconstituted), Rx only, Manufactured for Lupin Pharmaceuticals, Inc. 111 South Calvert Street, Baltimore, MD 21202, Manufactured by Lupin Limited Mumbai 400 058 India, NDC 27437-207-02.

Reason for Recall

Failed Impurities/Degradation Specifications: Product did not meet specification in total impurities at the 9-month stability station.

Distribution Pattern

Nationwide

Code Information

Lot #s: F300737 Exp. February 2015, F300743 Exp. February 2015

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1186-2014
openFDA file date
Oct 23, 2026
Loaded by RegDataLab
Oct 25, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.